Trial Profile
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (greater than or equal to 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Ibrutinib (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 31 Jan 2024 Planned End Date changed from 19 Jan 2024 to 30 Jan 2025.
- 02 Feb 2023 Planned End Date changed from 19 Jan 2023 to 19 Jan 2024.
- 17 Jun 2022 Results meta-analysis of randomized controlled trials from NCT0101006, NCT01886872, NCT01056510, and NCT03336333, presented at the 27th Congress of the European Haematology Association